Halaven 0.44 mg/mL eribulin solution vial 2 mL

Description

Metastatic Breast Cancer

• HALAVEN (eribulin mesylate) Injection is indicated for the treatment of patients with metastatic breast cancer (mBC) who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

Liposarcoma

• HALAVEN is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

How to use:

• Recommended dose is 1.4mg/m2 inA quick 2- to 5-minute infusion.

Caution & Warnings:

• Neutropenia
• Peripheral Neuropathy
• Embryo-Fetal Toxicity
• QT Prolongation

Side Effects:

• neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions

Ingredients:

• eribulin mesylate 1mg/2ml.